Drugs / Terazosin
Terazosin
also known as
Hytrin · ABBOTT-45975 · ABBOTT-45975 ANHYDROUS · Benph · Heitrin · Hytracin · Hytrin bph · Itrin · +14 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | HYTRIN | — | 1987-08-07 | fda.gov ↗ |
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07224269 | May 2026 → May 2027 expected | amyotrophic lateral sclerosis, platelet adenylate cyclase activity | University of Iowa | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04551040 | Mar 2021 → Mar 2023 overdue | — | University of Iowa | Active not recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04760860 | Oct 2027 → Oct 2030 expected | Lewy body dementia | Qiang Zhang | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07288450 | Sep 2026 → Sep 2030 expected | Parkinson disease | Nandakumar Narayanan | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03905811 | Sep 2019 → Jun 2020 | Parkinson disease | Jordan Schultz | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07464028 | Jul 2026 → Jul 2030 expected | Parkinson disease | Nandakumar Narayanan | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05109364 | Sep 2022 → Mar 2026 overdue | Parkinson disease, REM sleep behavior disorder | Cedars-Sinai Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04386317 | Nov 2020 → Dec 2025 overdue | Parkinson disease, REM sleep behavior disorder | Cedars-Sinai Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03195673 | Mar 2018 → Nov 2019 | carotid stenosis | Capital Medical University | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07207057 | Sep 2025 → May 2031 expected | Parkinson disease | University College, London | Recruiting | No outcome recorded |
| Phase 3 | NCT06966804 | Jun 2025 → May 2026 overdue | — | Penang Hospital, Malaysia | Recruiting | No outcome recorded |
| Phase 3 | NCT06863558 | May 2025 → Mar 2026 overdue | intracerebral hemorrhage | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06863571 | Apr 2025 → Mar 2026 overdue | ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05855577 | Dec 2023 → May 2026 | Parkinson disease, metabolic disease | Santa Lucia Foundation IRCCS | Unknown | No outcome recorded |
| Phase 4 | NCT00449683 | Mar 2007 → Aug 2013 | isolated hyperchlorhidrosis | Thomas Jefferson University | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT01508637 | Jan 2012 → Dec 2015 | — | University of Washington | Unknown | No outcome recorded |
| — | NCT00563485 | Oct 2005 → Nov 2006 | benign prostatic hyperplasia | Hospital Authority, Hong Kong | Terminated | No outcome recorded |
| — | NCT00237510 | May 2005 → May 2006 | — | Thomas Jefferson University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 12 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01366664 Background | Apr 2011 → Apr 2012 | premature ejaculation | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02966717 Comparator | Aug → Oct 2016 | chronic kidney disease, nephrotic syndrome | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01530243 Comparator | Jan → Aug 2012 | urinary system disorder | Urmia University of Medical Sciences | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03653845 Background | Jul 2018 → Jul 2019 | hypertensive disorder, primary aldosteronism | Third Military Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT02046395 Background | Jan 2012 → Dec 2019 | hypertensive disorder, type 2 diabetes mellitus | Tulane University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00438113 Comparator | Dec 2009 → Sep 2016 | atrial fibrillation | Nova Scotia Health Authority | Completed | No outcome recorded |
| Phase 4 | NCT00687388 Comparator | May 2008 → Mar 2012 | benign prostatic hyperplasia | Samsung Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT02244255 Comparator | Aug 1998 → Jun 2000 | benign prostatic hyperplasia | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT00700583 Background | May → Jun 2008 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT00693199 Comparator | Jul → Oct 2006 | hypertensive disorder | Anhui Medical University | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Terazosin | “Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using...” NCT02966717 ↗28“Study drugs used will be terazosin (a drug given for the treatment of hypertension and benign prostatic hyperplasia) and dapoxetine (a new drug being studied for the treatment...” NCT01366664 ↗ “Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)” NCT00687388 ↗ “Terazosin (no less than 1 mg orally or via nasogastric tube, nightly) or Urapidil (100 mg in 30 mL saline, IV infusion at no less than 2 mL/h)” NCT06863558 ↗ “Terazosin (no less than 1 mg orally or via nasogastric tube, nightly)” NCT06863571 ↗ “Step 5 - Addition of Terazosin 1 mg po od.” NCT00438113 ↗ “doxazosin, prazosin, terazosin, clonidine” NCT00684489 ↗ “amlodipine 5-10 mg/d ; terazosin 2-6mg/d” NCT03653845 ↗ “terazosin (Hytrin)” NCT00000620 ↗ |
| Known as | ABBOTT-45975 | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | ABBOTT-45975 ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Benph | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Heitrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Hytracin | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Hytrin | “Terazosin (Hytrin)” NCT07207057 ↗ |
| Known as | Hytrin bph | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Itrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | NSC-759168 | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Terazosabb | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Terazosin (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | terazosin (Hytrin) | “terazosin (Hytrin)” NCT00000620 ↗ |
| Known as | Terazosin hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Terazosin hcl 2h20 | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | TERAZOSIN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Terazosin hydrochloride anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Terazosin hydrochloride dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | TERAZOSIN HYDROCHLORIDE HYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Terazosina | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Terazosine | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Tezruly | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Known as | Urodie | ChEMBL registry synonym — accepted as the source's own label CHEMBL611 ↗ |
| Action | Inhibit | “a blocker of alpha-1 receptors” NCT00237510 ↗ |
| Modality | Small molecule | — CHEMBL611 ↗ |
| Route | Oral | “Addition of Terazosin 1 mg po od” NCT00438113 ↗ |